Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus Chemotherapy in Advanced Mesothelioma
NCT02784171Phase 3Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Nov 2016
- Primary completion
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 3 trial of pembrolizumab in malignant pleural mesothelioma (MPM), sponsored by Canadian Cancer Trials Group. Started Nov 2016; status: completed.
02
Drugs
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT02784171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02784171.